Array-based pharmacogenomics of molecular-targeted therapies in oncology

Pharmacogenomics Journal

Volumn 12, Issue 3, 2012, Pages 185-196

  Sanoudou, D ^a   Mountzios, G ^b   Arvanitis, D A ^c   Pectasides, D ^d  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

cetuximab; erlotinib; gefitinib; molecular targeted agents; trastuzumab

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CELECOXIB; CETUXIMAB; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 1; IMATINIB; LAPATINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; NILOTINIB; PURVALANOL A; RAPAMYCIN; RETINOIC ACID; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TANESPIMYCIN; TAXANE DERIVATIVE; TOZASERTIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UO 126; VANDETANIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; APOPTOSIS; BREAST CANCER; BREAST TUMOR; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; COLON ADENOCARCINOMA; COLORECTAL CANCER; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HEAD AND NECK CANCER; HUMAN; LEIOMYOSARCOMA; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; NON MELANOMA SKIN CANCER; NONHUMAN; ONCOLOGY; PANCREAS ADENOCARCINOMA; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ECONOMICS, PHARMACEUTICAL; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84861422473     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.53     Document Type: Review

References (112)

1. Mountzios G, Sanoudou D, Syrigos KN. Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies. Curr Pharm Des 2010; 16: 2184-2193.
2. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-826. (Pubitemid 32801464)
3. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ et al. Alphamethylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002; 62: 2220-2226. (Pubitemid 34411693)
4. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662-1670. (Pubitemid 34289218)
5. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-816. (Pubitemid 38121040)
6. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005; 65: 2170-2178. (Pubitemid 40490124)
7. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147. (Pubitemid 41653105)
8. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790-13795. (Pubitemid 33115977)
9. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009. (Pubitemid 35461656)
10. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
11. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536. (Pubitemid 34130608)
12. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
13. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 2004; 104: 2646-2654. (Pubitemid 39434943)
14. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. (Pubitemid 34651353)
15. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74. (Pubitemid 34101731)
16. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369. (Pubitemid 36957839)
17. Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 2009; 35: 354-363.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. (Pubitemid 38637993)
19. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. (Pubitemid 38720929)
20. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311. (Pubitemid 39209661)
21. Solmi R, Lauriola M, Francesconi M, Martini D, Voltattorni M, Ceccarelli C et al. Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer 2008; 8: 227.
22. Hopfner M, Sutter AP, Gerst B, Zeitz M, Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 2003; 89: 1766-1775. (Pubitemid 37464152)
23. Inoue R, Matsuyama H, Yano S, Yamamoto Y, Iizuka N, Naito K. Gefitinib-related gene signature in bladder cancer cells identified by a cDNA microarray. Anticancer Res 2006; 26(6B): 4195-4202. (Pubitemid 46031491)
24. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007; 13: 5869-5875. (Pubitemid 47583913)
25. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn Jr PA et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007; 6: 1683-1691. (Pubitemid 46954044)
26. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008; 68: 2391-2399. (Pubitemid 351521814)
27. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 2006; 4: 521-528. (Pubitemid 44341362)
28. Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald V, Maitra A, Iacobuzio-Donahue C et al. Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol Cancer Ther 2007; 6: 1079-1088. (Pubitemid 46554579)
29. Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A et al. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci USA 2005; 102: 11858-11863. (Pubitemid 41170815)
30. Kakiuchi S, Daigo Y, Ishikawa N, Furukawa C, Tsunoda T, Yano S et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004; 13: 3029-3043. (Pubitemid 40045258)
31. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007; 8: 258.
32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. (Pubitemid 41058344)
33. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. (Pubitemid 46972777)
34. Yang SX, Simon RM, Tan AR, Nguyen D, Swain SM. Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 2005; 11: 6226-6232. (Pubitemid 41262952)
35. Buchanan FG, Holla V, Katkuri S, Matta P, DuBois RN. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 2007; 67: 9380-9388. (Pubitemid 47535928)
36. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328-3335. (Pubitemid 40524617)
37. Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, Black EP. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics 2006; 7: 289.
38. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
39. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. (Pubitemid 43209104)
40. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
41. Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009; 27: 2751-2757.
42. Daemen A, Gevaert O, De Bie T, Debucquoy A, Machiels JP, De Moor B et al. Integrating microarray and proteomics data to predict the response on cetuximab in patients with rectal cancer. Pac Symp Biocomput 2008: 166-177.
43. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
44. Balko JM, Black EP. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 2009; 9: 145.
45. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW et al. Identification of heregulin, a specific activator of p185erbB2. Science 1992; 256: 1205-1210.
46. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney Jr DW et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 756-760. (Pubitemid 36227628)
47. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003; 63: 132-139. (Pubitemid 36070431)
48. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T et al. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2005; 280: 2092-2104.
49. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002; 3: 137-144.
50. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002; 29: 231-245. (Pubitemid 34620440)
51. Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, Walz TM et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 2003; 63: 2194-2199. (Pubitemid 36538626)
52. Willis S, Hutchins AM, Hammet F, Ciciulla J, Soo WK, White D et al. Detailed gene copy number and RNA expression analysis of the 17q12-23 region in primary breast cancers. Genes Chromosomes Cancer 2003; 36: 382-392. (Pubitemid 36314521)
53. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423. (Pubitemid 36842560)
54. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
55. Vegran F, Boidot R, Coudert B, Fumoleau P, Arnould L, Garnier J et al. Gene expression profile and response to trastuzumab-docetaxelbased treatment in breast carcinoma. Br J Cancer 2009; 101: 1357-1364.
56. Gu L, Lau SK, Loera S, Somlo G, Kane SE. Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. Clin Cancer Res 2009; 15: 7196-7206.
57. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
58. Kim HP, Han SW, Kim SH, Im SA, Oh DY, Bang YJ et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinibresistant lung cancer cells. Mol Cancer Ther 2008; 7: 607-615.
59. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13: 4909-4919. (Pubitemid 47294799)
60. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639. (Pubitemid 43259947)
61. Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007; 67: 1170-1175.
62. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15: 924-934.
63. Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 2007; 6: 1629-1640. (Pubitemid 46954030)
64. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008; 272: 296-306.
65. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J et al. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 2009; 4: e5933.
66. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30: 1426-1447.
67. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer 2008; 44: 2781-2790.
68. Havaleshko DM, Smith SC, Cho H, Cheon S, Owens CR, Lee JK et al. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia 2009; 11: 1185-1193.
69. Du Y, Wang K, Fang H, Li J, Xiao D, Zheng P et al. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood 2006; 107: 1582-1590. (Pubitemid 43242397)
70. McLean LA, Gathmann I, Capdeville R, Polymeropoulos MH, Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 2004; 10(1 Part 1): 155-165. (Pubitemid 38114174)
71. Kaneta Y, Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H et al. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res 2002; 93: 849-856. (Pubitemid 35012244)
72. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794-2799.
73. Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, Lebrigand K et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther 2009; 8: 1924-1933.
74. Quek R, George S. Gastrointestinal stromal tumor: a clinical overview. Hematol Oncol Clin North Am 2009; 23: 69-78, viii.
75. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res 2006; 12: 152-158. (Pubitemid 43166189)
76. Vitali R, Mancini C, Cesi V, Tanno B, Mancuso M, Bossi G et al. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models. Clin Cancer Res 2008; 14: 4622-4630.
77. Ochs MF, Rink L, Tarn C, Mburu S, Taguchi T, Eisenberg B et al. Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. Cancer Res 2009; 69: 9125-9132.
78. Moses AV, Jarvis MA, Raggo C, Bell YC, Ruhl R, Luukkonen BG et al. A functional genomics approach to Kaposi's sarcoma. Ann N Y Acad Sci 2002; 975: 180-191. (Pubitemid 36126961)
79. Price ND, Trent J, El-Naggar AK, Cogdell D, Taylor E, Hunt KK et al. Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci USA 2007; 104: 3414-3419. (Pubitemid 46364173)
80. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
81. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007; 67: 2226-2238. (Pubitemid 46424242)
82. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661. (Pubitemid 40053752)
83. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401. (Pubitemid 38938156)
84. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541. (Pubitemid 43882349)
85. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell 2004; 6: 209-214. (Pubitemid 39222033)
86. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4: 470-480. (Pubitemid 38745532)
87. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189. (Pubitemid 41507982)
88. Paripati A, Kingsley C, Weiss GJ. Pathway targets to explore in the treatment of small cell and large cell lung cancers. J Thorac Oncol 2009; 4: 1313-1321.
89. Weiss GJ, Kingsley C. Pathway targets to explore in the treatment of non-small cell lung cancer. J Thorac Oncol 2008; 3: 1342-1352.
90. Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 2007; 8: R255.
91. Wang C, Maass T, Krupp M, Thieringer F, Strand S, Worns MA et al. A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. J Hepatol 2009; 50: 1122-1131.
92. Cheepala SB, Yin W, Syed Z, Gill JN, McMillian A, Kleiner HE et al. Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer 2009; 8: 27.
93. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L et al. Ras pathway activation in hepatocellular carcinoma and antitumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009; 51: 725-733.
94. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009; 119: 1727-1740.
95. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M et al. Identifying genotype-dependent efficacy of single and combined PI3Kand MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 2009; 106: 18351-18356.
96. Ji RR, de Silva H, Jin Y, Bruccoleri RE, Cao J, He A et al. Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities. PLoS Comput Biol 2009; 5: e1000512.
97. von Eyben FE. Epidermal growth factor receptor inhibition and nonsmall cell lung cancer. Crit Rev Clin Lab Sci 2006; 43: 291-323.
98. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355: 570-580. (Pubitemid 44200650)
99. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12: 1294-1300. (Pubitemid 44706932)
100. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R et al. Retraction: genomic signatures to guide the use of chemotherapeutics. Nat Med 2011; 17: 135.
101. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J et al. Retraction: a genomic strategy to refine prognosis in early-stage nonsmall-cell lung cancer. N Engl J Med 2006; 355: 570-580.
102. N Engl J Med 2011; 364(12): 1176.
103. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana- Hulin M et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007; 8: 1071-1078. (Pubitemid 350182953)
104. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M et al. Retraction-validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2011; 12: 116.
105. Linton K, Hey Y, Dibben S, Miller C, Freemont A, Radford J et al. Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. Biotechniques 2009; 47: 587-596.
106. Roberts L, Bowers J, Sensinger K, Lisowski A, Getts R, Anderson MG. Identification of methods for use of formalin-fixed, paraffin-embedded tissue samples in RNA expression profiling. Genomics 2009; 94: 341-348.
107. Schwers S, Reifenberger E, Gehrmann M, Izmailov A, Bohmann K. A high-sensitivity, medium-density, and target amplification-free planar waveguide microarray system for gene expression analysis of formalin-fixed and paraffin-embedded tissue. Clin Chem 2009; 55: 1995-2003.
108. Jacobson TA, Lundahl J, Mellstedt H, Moshfegh A. Gene expression analysis using long-term preserved formalin-fixed and paraffinembedded tissue of non-small cell lung cancer. Int J Oncol 2011; 38: 1075-1081.
109. Grenert JP, Smith A, Ruan W, Pillai R, Wu AH. Gene expression profiling from formalin-fixed, paraffin-embedded tissue for tumor diagnosis. Clin Chim Acta 2011; 412: 1462-1464.
110. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
111. Shendure J. The beginning of the end for microarrays? Nat Methods 2008; 5: 585-587. (Pubitemid 351911858)
112. Sanoudou D. Pharmacogenomics: achievements, challenges and prospects, for patients, pharmaceutical industries and healthcare systems. Curr Pharm Des 2010; 16: 2182-2183.